. Author manuscript; available in PMC: 2014 Dec 1.

Published in final edited form as: BioDrugs. 2013 Dec;27(6):10.1007/s40259-013-0046-1. doi: 10.1007/s40259-013-0046-1

Table 2.

Anti-Viral Compounds Currently Tested in Rodent Models of Ebola Infection

	Therapeutic targets	Prophylactic efficacy	Therapeutic efficacy	Concerns	References
FGI-103, 104 and 106	Unknown	Yes FGI-106: 2 ~ 5 mg/kg BW ^* (single dose)	Yes FGI-103: 10 mg/kg BW^, (single dose) FGI-104: 10 mg/kg BW^/day (11 doses), FGI-106: 5 mg/kg BW^* (3 doses)	Multiple doses required	131–133
NSC62914	Reactive oxygen species (ROS)	Partial protection 2 mg/kg BW ^* (3 times)	Partial protection 2 ~ 5 mg/kg BW^* (3 doses)	Multiple doses required	144
Small interfering RNAs (siRNA)	L polymerase + VP24 + VP35	Not tested	Yes 0.75 ~ 1 mg/kg BW^* (7 doses)	Multiple doses required	122
Phosphorodiamid ate morphino oligo nucleotides (PMOs)	VP24+VP35; L polymerase + VP24 + VP35	Yes 5–50 μg (twice)	Yes 12.5 ~ 100 mg (11 doses)	Multiple doses required	127, 128
Monoclonal neutralizing Antibodies (NABs)	Ebola Virion (KZ52)	Not tested	Yes 50 mg/kg BW^* (single dose)	Multiple doses required	194
Triple monoclonal antibody cocktail	Ebola GP	Yes 100 μg (single dose)	Yes 100 μg (single dose)	Must be used early before/after exposure.	107
S-adenosyl-L-homocysteine hydrolase inhibitors	S-adenosyl-L-homocysteine hydrolase	Yes Ca-C³Ado: 80 mg/kg BW^, (single dose) C-NpcA: 1 mg/kg BW^ (single dose)	Yes Ca-C³Ado: 80 mg/kg BW^, (3 doses) C-NpcA: 1 mg/kg BW^ (3 doses)	Manipulation of host immune system	139, 140

BW: body weight